Skip directly to site content Skip directly to search


Español  Other Languages


Centers for Disease Control and Prevention. CDC twenty four seven. Saving Lives, Protecting People
 Search
		×
			Vaccines site
			Vaccines site
				All CDC
				Submit
			For a full list of topics:A-Z Index
			Advanced Search
		Advanced Search


Vaccines & Immunizations








Archived COVID-19 Vaccination Schedules						Print
																Related Pages
										**This web page is archived for historical purposes and is no longer being updated. Please go to CDC Home or use the A-Z Index or Search for more recent information.**
The August 22, 2022 COVID-19 vaccination schedules below were the most recent revision to the schedules prior to the initial authorization of bivalent mRNA COVID-19 boosters on August 31, 2022. They should be used for historical and research purposes only.
CDC’s Interim Clinical Considerations for the Use of COVID-19 Vaccines Currently Approved or Authorized in the United States should be consulted for current COVID-19 vaccination schedules and guidance. The Advisory Committee on Immunization Practices (ACIP) COVID-19 vaccine recommendations provide additional information.ARCHIVED COVID-19 vaccination schedule for people who are NOT moderately or severely immunocompromised, August 22, 2022
6 months through 11 yearsCOVID-19 vaccination schedule for people who are NOT moderately or severely immunocompromised: Aged 6 months through 11 years
Manufacturer
Age
group
Total number of doses recommended
Number of primary doses*
Number of booster doses†
Interval between 1st and 2nd dose‡
Interval between 2nd and 3rd dose
Interval between 3rd and 4th doseModerna
6 months–5 years
2
2
NA
4–8 weeks
NA
NAModerna
6–11 years
2
2
NA
4–8 weeks
NA
NAPfizer-BioNTech
6 months–4 years
3
3
NA
3–8 weeks
At least 8 weeks
NAPfizer-BioNTech
5–11 years
3
2
1
3–8 weeks
At least 5 months
NA12 through 17 yearsCOVID-19 vaccination schedule for people who are NOT moderately or severely immunocompromised: Aged 12 through 17 years
Manufacturer
Age
group
Total number of doses recommended
Number of primary doses*
Number of booster doses†
Interval between 1st and 2nd dose‡
Interval between 2nd and 3rd dose
Interval between 3rd and 4th doseModerna
12–17 years
2
2
NA
4–8 weeks
NA
NANovavax
12–17 years
2
2
NA
3–8 weeks
NA
NAPfizer-BioNTech
12–17 years
3
2
1
3–8 weeks
At least 5 months
NA18 years and olderCOVID-19 vaccination schedule for people who are NOT moderately or severely immunocompromised: Aged 18 years and older†
Manufacturer
Age
group
Total number of doses recommended
Number of primary doses*
Number of booster doses†
Interval between 1st and 2nd dose‡
Interval between 2nd and 3rd dose
Interval between 3rd and 4th doseModerna
18–49 years
3
2
1
4–8 weeks
At least 5 months
NAModerna
50 years and older
4
2
2
4–8 weeks
At least 5 months
At least 4 monthsNovavax
18 years and older
2
2
NA
3–8 weeks
NA
NAPfizer-BioNTech
18–49 years
3
2
1
3–8 weeks
At least 5 months
NAPfizer-BioNTech
50 years and older
4
2
2
3–8 weeks
At least 5 months
At least 4 monthsJanssen
18–49 years
2
1
1§
At least 2 months
NA
NAJanssen
50 years and older
3
1
2
At least 2 months
At least 4 months
NAFootnotes**Abbreviation**: NA = not authorized
*For primary series vaccination, Moderna, Novavax, and Pfizer-BioNTech COVID-19 vaccines are recommended. Janssen COVID-19 Vaccine should only be used in limited situations.
**†**For booster vaccination, Moderna and Pfizer-BioNTech are recommended and must be used for the second booster dose. Janssen COVID-19 Vaccine should only be used in limited situations. Currently, a booster dose using any COVID-19 vaccine is not authorized for people ages 6–17 years who receive a Moderna primary series or people ages 12 years and older who receive a Novavax primary series.
‡An **8-week** interval between the first and second primary series doses of Moderna, Novavax, and Pfizer-BioNTech COVID-19 vaccines may be optimal for some people ages 6 months–64 years, especially for males ages 12–39 years, as it may reduce the small risk of myocarditis/pericarditis associated with these vaccines. A shorter interval (3 weeks for Novavax and Pfizer-BioNTech; 4 weeks for Moderna) between the first and second doses remains the recommended interval for people who are moderately or severely immunocompromised; adults ages 65 years and older; and in situations in which there is increased concern about COVID-19 Community Levels or an individual’s higher risk of severe disease.
§People ages 18–49 years who received Janssen COVID-19 Vaccine as both their primary dose and first booster dose may receive a second booster dose using an mRNA vaccine at least 4 months after the first booster dose.
Top of PageARCHIVED COVID-19 vaccination schedule for people who ARE moderately or severely immunocompromised, August 22, 2022
6 months through 11 yearsCOVID-19 vaccination schedule for people who ARE moderately or severely immunocompromised: Aged 6 months through 11 years
Manufacturer
Age
group
Total number of doses recommended
Number of primary doses*
Number of booster doses†
Interval between 1st and 2nd dose
Interval between 2nd and 3rd dose
Interval between 3rd and 4th dose
Interval between 4th and 5th doseModerna
6 months–5 years
3
3
NA
4 weeks
At least 4 weeks
NA
NAModerna
6–11 years
3
3
NA
4 weeks
At least 4 weeks
NA
NAPfizer-BioNTech
6 months–4 years
3
3
NA
3 weeks
At least 8 weeks
NA
NAPfizer-BioNTech
5–11 years
4
3
1
3 weeks
At least 4 weeks
At least 3 months
NA12 through 17 yearsCOVID-19 vaccination schedule for people who ARE moderately or severely immunocompromised: Aged 12 through 17 years
Manufacturer
Age
group
Total number of doses recommended
Number of primary doses*
Number of booster doses†
Interval between 1st and 2nd dose
Interval between 2nd and 3rd dose
Interval between 3rd and 4th dose
Interval between 4th and 5th doseModerna
12–17 years
3
3
NA
4 weeks
At least 4 weeks
NA
NANovavax
12–17 years
2
2
NA
3 weeks
NA
NA
NAPfizer-BioNTech
12–17 years
5
3
2
3 weeks
At least 4 weeks
At least 3 months
At least 4 months18 years and olderCOVID-19 vaccination schedule for people who ARE moderately or severely immunocompromised: Aged 18 years and older†
Manufacturer
Age
group
Total number of doses recommended
Number of primary doses*
Number of booster doses†
Interval between 1st and 2nd dose
Interval between 2nd and 3rd dose
Interval between 3rd and 4th dose
Interval between 4th and 5th doseModerna
18 years and older
5
3
2
4 weeks
At least 4 weeks
At least 3 months
At least 4 monthsNovavax
18 years and older
2
2
NA
3 weeks
NA
NA
NAPfizer-BioNTech
18 years and older
5
3
2
3 weeks
At least 4 weeks
At least 3 months
At least 4 monthsJanssen
18 years and older
4
2
(1 Janssen, followed by 1 mRNA)
2
At least 4 weeks
At least 2 months
At least 4 months
NAFootnotes**Abbreviation**: NA = not authorized
*For primary series vaccination, Moderna, Novavax, and Pfizer-BioNTech COVID-19 vaccines are recommended; Janssen COVID-19 Vaccine should only be used in limited situations.
**†**For booster vaccination, Moderna and Pfizer-BioNTech are recommended and must be used for the second booster dose. Janssen COVID-19 Vaccine should only be used in limited situations. Currently, a booster dose using any COVID-19 vaccine is not authorized for people ages 6–17 years who receive a Moderna primary series or people ages 18 years and older who receive a Novavax primary series.
Top of Page
							
					
							Last Reviewed:  September 2, 2022						Source: 	National Center for Immunization and Respiratory Diseases
					Facebook
        Twitter
        LinkedIn
        Syndicate homeCOVID-19 Vaccination
Product Info by U.S. Vaccineplus icon
EUA
EUI
Interim Clinical Considerationsplus icon
Use of COVID-19 Vaccines in the U.S.
Use of COVID-19 Vaccines in the U.S.: Appendices
FAQs for the Interim Clinical Considerations
Myocarditis and Pericarditis Considerations
Clinical Care
Provider Requirements and Support
Vaccine Recipient Educationplus icon
Talking with Patients about COVID-19 Vaccination
How to Tailor COVID-19 Information to Your Audience
How to Address COVID-19 Vaccine Misinformation
Health Departments
Planning & Partnerships
6 Things to Know
Equity in Childhood COVID-19 Vaccination
COVID-19 Vaccine Data Systemsplus icon
Overviewplus icon
Vaccine IT Overview
Data Reporting Requirements
Vaccine Administration Management System (VAMS)plus icon
Getting Started in VAMS
General Public User
Resources for Jurisdictions, Clinics, and Organizations
VAMS Program Information
Vaccinate with Confidenceplus icon
What Is Vaccine Confidence?
Vaccine Confidence Strategies
Rapid Community Assessment Guide
COVID-19 Vaccine Confidence Data
12 COVID-19 Vaccination Strategies for Your Community
How to Engage the Arts to Build COVID-19 Vaccine Confidence
Strategies for Reaching People with Limited Access to COVID-19 Vaccines


About CDC
					Contact Us
					800-232-4636
 Facebook Twitter Instagram LinkedIn Youtube Pinterest Snapchat
 CONTACT CDC
				Contact Us
							Call 800-232-4636
							Email Us
			ABOUT CDC
				About CDC
							Jobs
							Funding
			POLICIES
				Accessibility
							External Links
							Privacy
							Policies
							No Fear Act
							FOIA
							OIG
							Nondiscrimination
							Vulnerability Disclosure Policy
			CONNECT WITH US
				Facebook
								Twitter
								Instagram
								LinkedIn
							Youtube
								Pinterest
								Snapchat
								Email
			LANGUAGES
				Español
							繁體中文
							Tiếng Việt
							한국어
							Tagalog
							Русский
							العربية
							Kreyòl Ayisyen
							Français
							Polski
							Português
							Italiano
							Deutsch
							日本語
							فارسی
							English


U.S. Department of Health & Human Services
			Accessibility
			External Links
			Privacy
			Policies
			No Fear Act
			FOIA
			Nondiscrimination
			OIG
			Vulnerability Disclosure Policy
			USA.gov


Exit Notification / Disclaimer Policy Close
 Links with this icon  indicate that you are leaving the CDC website. The Centers for Disease Control and Prevention (CDC) cannot attest to the accuracy of a non-federal website.
				Linking to a non-federal website does not constitute an endorsement by CDC or any of its employees of the sponsors or the information and products presented on the website.
				You will be subject to the destination website's privacy policy when you follow the link.
				CDC is not responsible for Section 508 compliance (accessibility) on other federal or private website. Website Disclaimers
 Cancel Continue